1-4 of 4
Lina Jin
Close
Sort by
Journal Articles

Updated Results of a Phase I Open-Label Single-Arm Study of Dual Targeting BCMA and CD19 Fastcar-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Juan Du, Wanting Qiang, Jing Lu, Yanchun Jia, Haiyan He, Jin Liu, Pei Guo, Ying Yang, Zhongyuan Feng, Lina Jin, Xiaoqiang Fan, Jia Liu, Qi Zhang, Lianjun Shen, Lihong Weng, Wenling Li, Wei Cao
Journal: Blood
Blood (2023) 142 (Supplement 1): 1022.
https://doi.org/10.1182/blood-2023-174841
Published: 2023
Journal Articles

Phase I Open-Label Single-Arm Study of BCMA/CD19 Dual-Targeting FasTCAR-T Cells (GC012F) As First-Line Therapy for Transplant-Eligible Newly Diagnosed High-Risk Multiple Myeloma

Juan Du, Weijun Fu, Jing Lu, Wanting Qiang, Haiyan He, Jin Liu, Ying Yang, Zhongyuan Feng, Lina Jin, Xiaoqiang Fan, Jia Liu, Qi Zhang, Lianjun Shen, Lihong Weng, Wei Cao
Journal: Blood
Blood (2022) 140 (Supplement 1): 889–890.
https://doi.org/10.1182/blood-2022-162295
Published: 2022
Journal Articles

Macrofocal Multple Myeloma Is a Particular Subgroup of Multiple Myeloma

Jianling Fan, MD, Jian Hou, MD PhD, Juan Du, MD PhD, Lina Jin, Lihui Peng, Baoan Chen, PhD Professor, Hao Xi, Hui Zhang, Hua Jiang, MD, Fan Zhou, Weijun Fu, MD
Journal: Blood
Blood (2015) 126 (23): 1855.
https://doi.org/10.1182/blood.V126.23.1855.1855
Published: 2015
Journal Articles

Anti-Cancer Effects of Rapamycin on U937 Cell Line.

Lina Jin, Chenchen Fu, Jiannong Cen, Peishuai Chen, De Pei Wu
Journal: Blood
Blood (2007) 110 (11): 4518.
https://doi.org/10.1182/blood.V110.11.4518.4518
Published: 2007